Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.
Howard I. Scher
Consultant or Advisory Role - Medivation (U)
Research Funding - Medivation
Karim Fizazi
No relevant relationships to disclose
Fred Saad
Consultant or Advisory Role - Medivation
Honoraria - Medivation
Research Funding - Medivation
Mary-Ellen Taplin
Consultant or Advisory Role - Medivation; Medivation
Research Funding - Medivation; Medivation
Cora N. Sternberg
No relevant relationships to disclose
Kurt Miller
Consultant or Advisory Role - Astellas Pharma; Medivation
Honoraria - Astellas Pharma
Ronald De Wit
No relevant relationships to disclose
Peter Mulders
Disclosure not yet available
Mohammad Hirmand
Employment or Leadership Position - Medivation
Bryan Selby
Employment or Leadership Position - Medivation
Johann Sebastian De Bono
Employment or Leadership Position - Institute of Cancer Research; Institute of Cancer Research
Consultant or Advisory Role - Astellas Pharma; Astellas Pharma; Johnson & Johnson; Johnson & Johnson; Medivation; Medivation
Honoraria - Astellas Pharma; Astellas Pharma; Johnson & Johnson; Johnson & Johnson; Medivation; Medivation